Immuneering reveals positive data from tumour treatment trial by John Pinching | Apr 20, 2023 | News | 0 IMM-1-104 found to be well tolerated with no dose limiting toxicities or serious adverse events Read More
DDF, Immuneering form $1.3m Alzheimer’s research collaboration by Selina McKee | Jun 18, 2018 | News | 0 Britain’s Dementia Discovery Fund has formed a research collaboration with US group Immuneering Corporation that aims to identify novel drug targets and candidates for Alzheimer’s disease. Read More